

Erratum to: Efficacy and safety of capecitabine plus cisplatin in Japanese patients with advanced or metastatic gastric cancer: subset analyses of the AVAGAST study and the ToGA study

Kensei Yamaguchi · Akira Sawaki · Toshihiko Doi · Taroh Satoh · Yasuhide Yamada · Yasushi Omuro · Tomohiro Nishina · Narikazu Boku · Keisho Chin · Yasuo Hamamoto · Hiroya Takiuchi · Yoshito Komatsu · Shigehira Saji · Wasaburo Koizumi · Yoshinori Miyata · Atsushi Sato · Eishi Baba · Takao Tamura · Takashi Abe · Atsushi Ohtsu

Published online: 13 November 2012

© The International Gastric Cancer Association and The Japanese Gastric Cancer Association 2012

Erratum to: Gastric Cancer DOI 10.1007/s10120-012-0167-0

In Table 5, the column headings “Grade 3” should be “Grade 3 or 4”.

The corrected table is shown here.

We sincerely apologize for the errors.

The online version of the original article can be found under doi:[10.1007/s10120-012-0167-0](https://doi.org/10.1007/s10120-012-0167-0).

K. Yamaguchi (✉)
Department of Gastroenterology, Saitama Cancer Center Hospital, 818 Komuro, Ina-machi, Kitaadachi-gun, Saitama 362-0806, Japan
e-mail: k-yamaguchi@cancer-c.pref.saitama.jp

A. Sawaki
Department of Gastroenterology, Aichi Cancer Center Hospital, Aichi, Japan

T. Doi
Gastrointestinal Oncology Division, National Cancer Center Hospital East, Chiba, Japan

T. Satoh
Department of Medical Oncology, Kinki University School of Medicine, Osaka, Japan

Y. Yamada
Department of Gastrointestinal Oncology, National Cancer Center Hospital, Tokyo, Japan

Y. Omuro
Department of Chemotherapy, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan

T. Nishina
Department of Internal Medicine, National Hospital Organization Shikoku Cancer Center, Ehime, Japan

N. Boku
Department of Gastroenterology, Shizuoka Cancer Center, Shizuoka, Japan

K. Chin
Department of Gastroenterology, JFCR Cancer Institute Ariake Hospital, Tokyo, Japan

Y. Hamamoto
Department of Medical Oncology, Tochigi Cancer Center, Tochigi, Japan

H. Takiuchi
Cancer Chemotherapy Center, Osaka Medical College, Osaka, Japan

Y. Komatsu
Third Department of Internal Medicine, Hokkaido University Hospital, Hokkaido, Japan

S. Saji
Department of Medical Oncology, Saitama Medical University International Medical Center, Saitama, Japan

W. Koizumi
Department of Gastroenterology, Kitasato University East Hospital, Kanagawa, Japan

Table 5 Summary of adverse events

	AVAGAST ^a (N = 94)		ToGA ^b (N = 50)		Total (N = 144)	
	All grades N (%)	Grade 3 or 4 N (%)	All grades N (%)	Grade 3 or 4 N (%)	All grades N (%)	Grade 3 or 4 N (%)
Total	94 (100)	71 (76)	50 (100)	36 (72)	144 (100)	107 (74)
Hematological toxicities						
Neutropenia	63 (67)	45 (48)	34 (68)	20 (40)	97 (67)	65 (45)
Thrombocytopenia	19 (20)	2 (2)	8 (16)	3 (6)	27 (19)	5 (3)
Anemia	16 (17)	10 (11)	11 (22)	8 (16)	27 (19)	18 (13)
Febrile neutropenia	5 (5)	5 (5)	3 (6)	3 (6)	8 (6)	8 (6)
Non-hematological toxicities						
Nausea	84 (89)	18 (19)	44 (88)	7 (14)	128 (89)	25 (17)
Vomiting	60 (64)	6 (6)	28 (56)	2 (4)	88 (61)	8 (6)
Diarrhea	51 (54)	4 (4)	24 (48)	2 (4)	75 (52)	6 (4)
Stomatitis	34 (36)	1 (1)	16 (32)	1 (2)	50 (35)	2 (1)
Abdominal pain	12 (13)	1 (1)	3 (6)	–	15 (10)	1 (<1)
Hand-foot syndrome	54 (57)	2 (2)	23 (46)	1 (2)	77 (53)	3 (2)
Rash	19 (20)	–	5 (10)	–	24 (17)	–
Anorexia	83 (88)	27 (29)	46 (92)	10 (20)	129 (90)	37 (26)
Fatigue	69 (73)	5 (5)	26 (52)	4 (8)	95 (66)	9 (6)
Peripheral neuropathy	28 (30)	2 (2)	10 (20)	–	38 (26)	2 (1)
Renal impairment	17 (18)	3 (3)	27 (54)	–	44 (31)	3 (2)
Increased lacrimation	2 (2)	–	1 (2)	–	3 (2)	–

^a The target population of the AVAGAST study was metastatic or inoperable locally advanced adenocarcinoma of the stomach or gastro-esophageal junction

^b The target population of the ToGA study was HER2-positive metastatic or inoperable locally advanced adenocarcinoma of the stomach or gastro-esophageal junction

Y. Miyata
Department of Gastroenterology, Saku Central Hospital,
Nagano, Japan

A. Sato
Department of Internal Medicine, Toyosu Hospital,
Showa University School of Medicine, Tokyo, Japan

E. Baba
Department of Hematology and Oncology, Kyushu University
Hospital, Fukuoka, Japan

T. Tamura
Division of Diabetes, Digestive, and Kidney Diseases,
Department of Clinical Molecular Medicine, Kobe University
Graduate School of Medicine, Hyogo, Japan

T. Abe
Internal Medicine, Yamagata Prefectural Central Hospital,
Yamagata, Japan

A. Ohtsu
Research Center for Innovative Oncology, National Cancer
Center Hospital East, Chiba, Japan